Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.33 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1983047 | 0.82 | ALDH1A1 (0.39) | ENPP2CYP1A2CYP3A4CYP2C9CYP1A1 | |
| SCHEMBL427184 | 0.81 | HCAR2 (0.33) | — | |
| SCHEMBL3660018 | 0.81 | CHRNB2 (0.31) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL458480 | 0.81 | ATM (0.33) | — | |
| SCHEMBL2067107 | 0.80 | KDM4E (0.32) | — | |
| SCHEMBL584540 | 0.80 | NPC1 (0.35) | CYP1A2CYP3A4 | |
| SCHEMBL3102053 | 0.79 | CYP1A1 (0.35) | CYP11B1CYP11B2MKNK2MKNK1ROCK2 | |
| SCHEMBL13451428 | 0.79 | ENPP2 (0.40) | CYP11B1CYP11B2ENPP2MKNK2MKNK1 | |
| SCHEMBL2068547 | 0.78 | CYP11B1 (0.35) | CYP11B1CYP11B2 | |
| SCHEMBL17651864 | 0.78 | KDM4E (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711359-A2 | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | Jazz Pharmaceuticals Research UK Limited (GB) | 2026-03-18 | — | — | EP | disclosed |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | disclosed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | disclosed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | disclosed |
| US-20240254066-A1 | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) | 2024-08-01 | — | — | US | disclosed |
| EP-4337315-A1 | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | GW Research Limited (GB) | 2024-03-20 | — | — | EP | disclosed |
| CN-117396455-A | Resorcinol, its manufacturing method and use | 吉伟研究有限公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-111808057-B | Suzuki reaction using alpha-O-alkenyl sulfone as electrophile and application thereof | 四川大学 | 2023-05-09 | — | — | CN | disclosed |
| CN-111808089-B | Preparation method of drug eprogliflozin for treating diabetes or derivative thereof | 四川大学华西医院 | 2023-04-11 | — | — | CN | disclosed |
| WO-2022238707-A1 | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | GW Research Limited (GB) | 2022-11-17 | — | — | WO | disclosed |
| EP-1934216-A1 | NAPHTHYRIDIN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008073785-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| WO-2007148093-A1 | ANTIBACTERIAL COMPOSITIONS | PROLYSIS LTD. (GB) | 2007-12-27 | — | — | WO | disclosed |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-08-23 | — | — | US | disclosed |
| EP-1786790-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2007039512-A1 | NAPHTHYRIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078155-A1 | Naphthyridin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-25 | — | — | US | disclosed |
| WO-2006019833-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | HCRTR1, HRH3, HCRTR2 | CYP11B1 1173/4885CYP11B2 1521/4885ENPP2 1856/4885 |
| US-20070078155-A1 | Naphthyridin derivatives | GRM5, GRM3, GRM1 | CYP11B1 1427/4885CYP11B2 1352/4885ENPP2 1206/4885 |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | CYP11B1 3658/4885CYP11B2 4114/4885ENPP2 3519/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | CYP11B1 3658/4885CYP11B2 4114/4885ENPP2 3519/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | CYP11B1 3658/4885CYP11B2 4114/4885ENPP2 3519/4885 |
| US-20240254066-A1 | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | REN, CYP46A1, NQO1 | CYP11B1 17/4885CYP11B2 18/4885ENPP2 317/4885 |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | CYP11B1 492/4885CYP11B2 334/4885ENPP2 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.